Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Brincidofovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 7/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brincidofovir SCHEMBL12918810 | 1.00 | FGFR1 (1.00) | FGFR1SLC22A6CYP3A4CYP2D6 | |
| SCHEMBL22863226 | 1.00 | FGFR1 (1.00) | FGFR1SLC22A6CYP3A4CYP2D6 | |
| SCHEMBL29708091 | 0.96 | FGFR1 (0.93) | FGFR1SLC22A6CYP3A4CYP2D6 | |
| SCHEMBL139865 | 0.94 | FGFR1 (0.88) | FGFR1SLC22A6CYP3A4CYP2D6 | |
| SCHEMBL16518411 | 0.93 | FGFR1 (0.86) | FGFR1SLC22A6CYP3A4CYP2D6 | |
| SCHEMBL25574828 | 0.92 | FGFR1 (0.85) | FGFR1SLC22A6CYP3A4CYP2D6 | |
| SCHEMBL10081920 | 0.92 | FGFR1 (0.84) | FGFR1SLC22A6CYP3A4CYP2D6 | |
| SCHEMBL16802851 | 0.91 | FGFR1 (0.84) | FGFR1SLC22A6CYP3A4CYP2D6 | |
| SCHEMBL16802854 | 0.91 | FGFR1 (0.84) | FGFR1SLC22A6CYP3A4CYP2D6 | |
| SCHEMBL20644394 | 0.91 | FGFR1 (0.84) | FGFR1SLC22A6CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 834 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144816-A1 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | claimed |
| EP-4506008-B1 | INTRAVENOUS ADMINISTRATION OF BRINCIDOFOVIR FOR THE TREATMENT OF ADENOVIRUS INFECTION OR DISEASE ASSOCIATED WITH ADENOVIRUS INFECTION | SYMBIO PHARMACEUTICALS LTD (JP) | 2026-05-27 | — | — | EP | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026100257-A1 | TREATMENT OF MALIGNANT TUMOR | シンバイオ製薬株式会社 | 2026-05-15 | — | — | WO | claimed |
| US-12611440-B2 | Fusion proteins and uses thereof | SYNKLINO A/S (DK) | 2026-04-28 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4721746-A1 | TREATMENT OF MALIGNANT TUMOR | SymBio Pharmaceuticals Limited (JP) | 2026-04-08 | — | — | EP | claimed |
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-12544392-B2 | Treatment of adenovirus infection or disease associated with adenovirus infection | SYMBIO PHARMACEUTICALS LIMITED (JP) | 2026-02-10 | — | — | US | claimed |
| US-11395816-B2 | Corroles for treating human cytomegalovirus infections | UNIVERSITE DE BOURGOGNE (FR) | 2022-07-26 | — | — | US | claimed |
| EP-4025591-A1 | FUSION PROTEINS AND USES THEREOF | Synklino ApS (DK) | 2022-07-13 | — | — | EP | claimed |
| CN-114732821-A | Application of cidofovir prodrug in preparation of African swine fever prevention and treatment medicines | 华中农业大学 | 2022-07-12 | — | — | CN | claimed |
| WO-2022126207-A1 | DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2022-06-23 | — | — | WO | claimed |
| CN-114558022-A | Application of brinell-cidofovir in preparation of anti-pseudorabies virus drugs | 华中农业大学 | 2022-05-31 | — | — | CN | claimed |
| EP-3989981-A1 | PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION | Topelia Australia Pty Ltd (AU) | 2022-05-04 | — | — | EP | claimed |
| WO-2022072842-A1 | METHODS OF TREATING BONE INFECTIONS | MICROBION CORPORATION (US) | 2022-04-07 | — | — | WO | claimed |
| CN-114191438-A | Methods of treating filoviridae virus infections | 吉利德科学公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | IRF3, ZC3HAV1, ZC3HAV1L | FGFR1 1429/4885SLC22A6 3660/4885CYP3A4 1156/4885 |
| US-11395816-B2 | Corroles for treating human cytomegalovirus infections | MGMT, RPL35, RPL5 | FGFR1 4263/4885SLC22A6 1805/4885CYP3A4 3633/4885 |
| US-20260144816-A1 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA | MAPT, MTOR, RICTOR | FGFR1 2443/4885SLC22A6 2396/4885CYP3A4 3239/4885 |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | ACE, MAVS, SARS1 | FGFR1 810/4885SLC22A6 4148/4885CYP3A4 1273/4885 |
| US-12544392-B2 | Treatment of adenovirus infection or disease associated with adenovirus infection | ACE, SLC10A1, SLC10A2 | FGFR1 409/4885SLC22A6 345/4885CYP3A4 243/4885 |
| US-12611440-B2 | Fusion proteins and uses thereof | TIMCC, CX3CR1, CXCL10 | FGFR1 1166/4885SLC22A6 2468/4885CYP3A4 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.